Cite
HARVARD Citation
Henry, N. et al. (2018). Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden. Journal of medical economics. pp. 318-325. [Online].